$PLSE News

Pulse Biosciences (PLSE) Stock Still Seems Rich Against Book Value

Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026

Pulse Biosciences (PLSE) Stock Fair Value Rises After Analyst Target Increases

Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center

Pulse Biosciences Partners With Clayman Thyroid Center At Hospital For Endocrine Surgery In Tampa, Florida

Pulse Biosciences' 2027 Trial Readout Crucial to Evaluate New Pulsed Field Ablation Modality, Oppenheimer Says

Oppenheimer Maintains Outperform on Pulse Biosciences, Raises Price Target to $60

Why Pulse Biosciences (PLSE) Is Up 12.3% After Full NANOPULSE-AF Enrollment And nPulse Spotlight

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026

Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment

Canaccord Genuity Maintains Buy on Pulse Biosciences, Raises Price Target to $58

Pulse Biosciences (PLSE) Stock Fair Value Rises After Analysts Back NsPFA Data

Pulse Biosciences: Promising Technology, But Hard To Justify Its Valuation

BTIG Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $70

Pulse Biosciences Files Prospectus Supplement For Up To $85M At-The-market Common Stock Offering Via Mizuho; Terminates TD Cowen Distribution Agreement On Sept 14, 2026 With $1M Unsold

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

Pulse Biosciences Concludes 100 Patient Enrollment in PRECISE-BTN Study of nPulse Vybrance Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

Freedom Capital Markets Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $73

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)